Aeglea Bio Therapeutics Stock Price To Sales

AGLEDelisted Stock  USD 0.59  0.01  1.72%   
Aeglea Bio Therapeutics fundamentals help investors to digest information that contributes to Aeglea Bio's financial success or failures. It also enables traders to predict the movement of Aeglea Stock. The fundamental analysis module provides a way to measure Aeglea Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aeglea Bio stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Aeglea Bio Therapeutics Company Price To Sales Analysis

Aeglea Bio's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

P/S

 = 

MV Per Share

Revenue Per Share

More About Price To Sales | All Equity Analysis

Current Aeglea Bio Price To Sales

    
  4.08 X  
Most of Aeglea Bio's fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aeglea Bio Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Competition

Based on the latest financial disclosure, Aeglea Bio Therapeutics has a Price To Sales of 4.0838 times. This is 80.92% lower than that of the Biotechnology sector and 95.85% lower than that of the Health Care industry. The price to sales for all United States stocks is 64.24% higher than that of the company.

Aeglea Price To Sales Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aeglea Bio's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Aeglea Bio could also be used in its relative valuation, which is a method of valuing Aeglea Bio by comparing valuation metrics of similar companies.
Aeglea Bio is currently under evaluation in price to sales category among its peers.

Aeglea Fundamentals

About Aeglea Bio Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Aeglea Bio Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aeglea Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aeglea Bio Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.

Other Consideration for investing in Aeglea Stock

If you are still planning to invest in Aeglea Bio Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aeglea Bio's history and understand the potential risks before investing.
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing